Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial.
Saved in:
| Title: | Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial. |
|---|---|
| Authors: | Dark P; Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Critical Care Unit, Northern Care Alliance NHS Foundation Trust, Salford Care Organization, Greater Manchester, United Kingdom., Hossain A; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., McAuley DF; Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, United Kingdom.; Royal Victoria Hospital Belfast, Belfast, United Kingdom., Brealey D; University College London Hospitals NHS Foundation Trust, United Kingdom., Carlson G; National Intestinal Failure Centre, Northern Care Alliance NHS Foundation Trust, Salford Care Organization, Greater Manchester, United Kingdom., Clayton JC; Department of Clinical Biochemistry, Lancashire Teaching Hospitals NHS Foundation Trust, Sharoe Green Lane, Fulwood, Preston Lancashire, United Kingdom., Felton TW; Respiratory Academic Group, Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Wythenshawe Hospital, Manchester, United Kingdom., Ghuman BK; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., Gordon AC; Division of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College London, London, United Kingdom., Hellyer TP; Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom.; University of Newcastle, Newcastle Upon Tyne, United Kingdom., Lone NI; Anaesthesia, Critical Care and Pain Medicine, Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh Royal Infirmary, Edinburgh, United Kingdom., Manazar U; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., Richards G; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., McCullagh IJ; Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom., McMullan R; Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, United Kingdom.; Royal Victoria Hospital Belfast, Belfast, United Kingdom., McNamee JJ; Royal Victoria Hospital Belfast, Belfast, United Kingdom., McNeil HC; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., Mouncey PR; Clinical Trials Unit, Intensive Care National Audit and Research Centre, Napier House, London, United Kingdom., Naisbitt MJ; Salford Royal Hospital, Manchester, United Kingdom., Parker RJ; Liverpool University NHS Foundation Trust, Aintree University Hospital, Liverpool, United Kingdom., Poole RL; CEDAR, Cardiff and Vale University Health Board, Wales, United Kingdom., Rostron AJ; University of Newcastle, Newcastle Upon Tyne, United Kingdom.; Sunderland Royal Hospital, United Kingdom., Singer M; Centre for Intensive Care Medicine, Experimental and Translational Medicine, Division of Medicine, Faculty of Medical Sciences, University College London, London, United Kingdom., Stevenson MD; Sheffield Centre for Health and Related Research, Regent Court, Sheffield, United Kingdom., Walsh TS; Anaesthesia, Critical Care and Pain Medicine, Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh Royal Infirmary, Edinburgh, United Kingdom., Welters ID; Royal Liverpool University Hospital, Liverpool, United Kingdom., Whitehouse T; Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom., Whiteley S; St James's University Hospital, Leeds, United Kingdom., Wilson P; Clinical Microbiology, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Young KK; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., Perkins GD; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom., Lall R; Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom. |
| Corporate Authors: | ADAPT-Sepsis Collaborators |
| Source: | JAMA [JAMA] 2025 Feb 25; Vol. 333 (8), pp. 682-693. |
| Publication Type: | Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1538-3598 |
|---|---|
| DOI: | 10.1001/jama.2024.26458 |
